New directions in asthma drug therapy.
A new generation of biologically informative treatments has altered our understanding of the disease--transforming what used to be viewed as a single entity into a family of airway disorders driven by different proinflammatory mediators. Although inhaled corticosteroids have been the treatment of choice for most patients, research is increasingly aimed at developing inhibitors targeted to specific effector systems.
Drazen
J M
JM
Harvard Medical School, Boston, USA.
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002867:Chromones / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives / Q000627:therapeutic use; D007211:Indoles; D007249:Inflammation; D015289:Leukotrienes / Q000276:immunology; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use*; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000627:therapeutic use
D018927:Anti-Asthmatic Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002867:Chromones; D007211:Indoles; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; C047681:pranlukast; C063449:zileuton; D006918:Hydroxyurea; C062735:zafirlukast